Features Screener Stocks Charts
Sign In Sign Up

Jenburkt Pharmaceuticals Cash Flow Statement

NSE:JENBURKT | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.87x

JENBURKT's operating cash flow covered 87% of net income in FY 2025. Some earnings may be tied up in working capital.

Free Cash Flow

₹81.92M

JENBURKT's free cash flow was ₹81.92M in FY 2025, up 47.1% from FY 2024.

Dividend Coverage

1.2x

JENBURKT's free cash flow covered dividends 1.2x in FY 2025 but leaves limited surplus.

CapEx Intensity

70.6%

Capital expenditure consumed 70.6% of operating cash flow in FY 2025 for JENBURKT, typical of capital-intensive industries.

2-year JENBURKT cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 259.77M 320.61M
Cash flow Operating Activities 81.24M 279.06M
Investments in PPE -25.54M -197.14M
Cash flow Investing Activities -5.80M -170.45M
Dividend Paid -63.18M -67.81M
Cash flow Financing Activities -70.78M -76.22M
Cash at beginning of period 36.60M 41.25M
Cash at end of period 41.25M 73.65M
Free Cash Flow 55.70M 81.92M

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025